Mirati Therapeutics, Inc. (MRTX) [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Dec-31-22	Sep-30-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21
	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q
Total revenue	27.2	18.9	12.4	11.8	78.2	72.8	72.1	73.5
Total revenue growth	-65.2%	-74.0%	-82.7%	-83.9%	495.2%	454.4%	438.0%	501.6%
Revenue
Total revenue	27.2	18.9	12.4	11.8	78.2	72.8	72.1	73.5
Total revenue growth	-65.2%	-74.0%	-82.7%	-83.9%	495.2%	454.4%	438.0%	501.6%
Operating expenses
Cost of product revenue	1.6	0.6	0.6
Research and development	523.2	527.3	531.6	544.2	529.3	535.5	508.6	437.5
Selling, general and administrative	149.0	127.7			108.2	54.0
Total operating expenses	806.5	788.1	772.0	756.7	716.2	697.8	645.3	555.9
Loss from operations	-779.3	-769.2	-759.6	-744.9	-638.0	-625.0	-573.2	-482.4
Operating margin	-2862.6%	-4071.1%	-6108.0%	-6312.5%	-816.2%	-858.5%	-795.1%	-656.4%
Other income (expense), net	42.2	32.6	19.2	7.2	-3.2	-6.2	-5.3	2.5
Net loss	-737.5	-737.1	-740.9	-738.0	-644.5	-634.5	-581.8	-483.3
Foreign currency translation adjustment	-9.6	-9.6	-9.6	-9.5
Unrealized gain (loss) on available-for-sale investments	2.1	1.1			-5.7	-4.8
Comprehensive loss	-742.6	-743.0	-753.7	-753.7	-650.7	-639.7	-582.5	-484.1

Basic net loss per share (USD per share)	($12.83)	($12.97)	($13.19)	($13.43)	($11.89)	($11.94)	($11.21)	($9.54)
Diluted net loss per share (USD per share)	($12.83)	($12.97)	($13.19)	($13.43)	($11.89)	($11.94)	($11.21)	($9.54)

Weighted average common shares outstanding, basic (shares)	57.2	56.5	55.9	54.8	53.6	52.6	51.4	49.7
Weighted average common shares outstanding, diluted (shares)	57.2	56.5	55.9	54.8	53.6	52.6	51.4	49.7